These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7875151

  • 21. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine.
    Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA.
    Blood; 1991 May 15; 77(10):2109-17. PubMed ID: 1709368
    [Abstract] [Full Text] [Related]

  • 22. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma.
    Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE.
    Am J Clin Oncol; 1991 May 15; 14 Suppl 1():S40-4. PubMed ID: 2048563
    [Abstract] [Full Text] [Related]

  • 23. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF, Chan HO.
    Pharmacotherapy; 2005 Mar 15; 25(3):372-8. PubMed ID: 15843284
    [Abstract] [Full Text] [Related]

  • 24. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R, Talpaz M, Gutterman JU.
    Am J Med; 1992 Jul 15; 93(1):41-8. PubMed ID: 1626572
    [Abstract] [Full Text] [Related]

  • 25. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS. The Oral Ganciclovir European and Australian Cooperative Study Group.
    AIDS; 1995 May 15; 9(5):471-7. PubMed ID: 7639972
    [Abstract] [Full Text] [Related]

  • 26. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma.
    Scadden DT, Bering HA, Levine JD, Bresnahan J, Evans L, Epstein C, Groopman JE.
    J Clin Oncol; 1991 May 15; 9(5):802-8. PubMed ID: 2016623
    [Abstract] [Full Text] [Related]

  • 27. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
    Kuppermann BD, Flores-Aguilar M, Quiceno JI, Rickman LS, Freeman WR.
    Arch Ophthalmol; 1993 Oct 15; 111(10):1359-66. PubMed ID: 8216016
    [Abstract] [Full Text] [Related]

  • 28. Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis.
    Weinberg DV, Murphy R, Naughton K.
    Am J Ophthalmol; 1994 Jun 15; 117(6):776-82. PubMed ID: 8198162
    [Abstract] [Full Text] [Related]

  • 29. Outcomes of granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor use in neutropenic patients infected with human immunodeficiency virus.
    Ambati BK, Perlman DC, Salomon N.
    Int J Infect Dis; 1994 Jun 15; 3(2):70-5. PubMed ID: 10225983
    [Abstract] [Full Text] [Related]

  • 30. Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo-controlled trial in AIDS patients.
    Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, Gharakhanian S, Rozenbaum W, GCS 309 European Study Group.
    Eur J Haematol; 2000 Nov 15; 65(5):337-43. PubMed ID: 11092465
    [Abstract] [Full Text] [Related]

  • 31. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI, Rivera F, Díaz-Puente MT, Lianes P, Colomer R, López-Brea M, López E, Paz-Ares L, Hitt R, García-Ribas I.
    J Natl Cancer Inst; 1995 Jun 07; 87(11):803-8. PubMed ID: 7540696
    [Abstract] [Full Text] [Related]

  • 32. Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994.
    Wutoh AK, Hidalgo J, Rhee W, Bareta J, Steidl S.
    Am J Health Syst Pharm; 1999 Jul 01; 56(13):1314-8. PubMed ID: 10683128
    [Abstract] [Full Text] [Related]

  • 33. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.
    Markham A, Faulds D.
    Drugs; 1994 Sep 01; 48(3):455-84. PubMed ID: 7527763
    [Abstract] [Full Text] [Related]

  • 34. Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment.
    Causey D.
    J Acquir Immune Defic Syndr (1988); 1991 Sep 01; 4 Suppl 1():S16-21. PubMed ID: 1848617
    [Abstract] [Full Text] [Related]

  • 35. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group.
    Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA.
    N Engl J Med; 1999 Apr 08; 340(14):1063-70. PubMed ID: 10194235
    [Abstract] [Full Text] [Related]

  • 36. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 37. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151.
    Jacobson MA, Kramer F, Bassiakos Y, Hooton T, Polsky B, Geheb H, O'Donnell JJ, Walker JD, Korvick JA, van der Horst C.
    J Infect Dis; 1994 Jul 18; 170(1):189-93. PubMed ID: 8014496
    [Abstract] [Full Text] [Related]

  • 38. Current management of cytomegalovirus disease in patients with AIDS.
    Jacobson MA.
    AIDS Res Hum Retroviruses; 1994 Aug 18; 10(8):917-23. PubMed ID: 7811543
    [Abstract] [Full Text] [Related]

  • 39. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.
    Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO.
    Bone Marrow Transplant; 1996 Jun 18; 17(6):951-6. PubMed ID: 8807099
    [Abstract] [Full Text] [Related]

  • 40. Advances in treatment for cytomegalovirus retinitis.
    Bowers M.
    BETA; 1995 Sep 18; ():13-5. PubMed ID: 11362885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.